Anti-inflammatory and Antiangiogenic Effects of Nanoparticle-Mediated Delivery of a Natural Angiogenic Inhibitor
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE: The purpose of this study was to evaluate the inhibitory effects of the nanoparticle-mediated delivery of plasminogen kringle 5 (K5) on choroidal neovascularization (CNV) and retinal inflammation. METHODS: CNV was induced by laser in adult rats. Nanoparticles with an expression plasmid of K5 (K5-NP) were injected into the vitreous. K5 expression was detected by immunohistochemistry. The CNV area was measured after fluorescein angiography. Retinal vascular permeability was quantified with Evans blue as a tracer. Expression of vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MCP)-1, and intercellular adhesion molecule (ICAM)-1 was measured by Western blot analysis or ELISA and real-time RT-PCR. RESULTS: Intense K5 expression was detected in the retina 2 weeks after the injection of K5-NP. Areas of CNV were significantly decreased in the K5-NP treatment group compared with that in the control-NP group. The K5-NP injection also significantly reduced vascular permeability. The expression of VEGF was downregulated by K5-NP at both the protein and mRNA levels. Moreover, K5-NP also inhibited expression of TNF-α and ICAM-1. Similarly, K5-NP decreased retinal levels of total β-catenin. In cultured cells, K5-NP suppressed hypoxia-induced secretion of MCP-1 and TNF-α. CONCLUSIONS: K5 has a novel anti-inflammatory activity. K5-NP mediates a sustained inhibitory effect on CNV and thus has therapeutic potential for age-related macular degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932
Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS Report No. 11
(2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.11.1621 · Cited by 374
Pathogenesis of lesions in late age-related macular disease
Holz, F. G., Pauleikhoff, D., Klein, R., & Bird, A. C. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.026 · Cited by 203 · cited 1×
“The abnormal vessels in the subretinal space can lead to hemorrhage, scar formation, and exudation, resulting in retinal detachment and vision loss.(1,2) CNV occurs in patients with the wet form of age-related macular degeneration (AMD), the most common cause of blindness among the elderly in developed countries.”
BackgroundInflammation, Complement Factor H, and Age-Related Macular Degeneration
Klein, R., Knudtson, M. D., Klein, B. E. K., Wong, T. Y., Cotch, M. F., Liu, K., Cheng, C. Y., Burke, G. L., Saad, M. F., Jacobs, D. R., et al. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.03.021 · Cited by 106 · cited 3×
“VEGF is a potent angiogenic stimulator that promotes proliferation and migration of vascular endothelial cells and enhances vascular permeability.22 Furthermore, it plays a key role in pathologic NV in both AMD and DR.23 Previous Co ntr olNP Co ntr olNP Co ntr olNP K5 -”
Background
Cited by
Jo, D. H., Kim, J. H., Lee, T. G., & Kim, J. H. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.04.015 · Cited by 433
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging
Kompella, U. B., Amrite, A. C., Pacha Ravi, R., & Durazo, S. A. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.04.001 · Cited by 258
Self-citationNanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107
Non-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80
An insight on ophthalmic drug delivery systems: focus on polymeric biomaterials-based carriers
Shafiq, M., Rafique, M., Cui, Y., Pan, L., Do, C.-W., & Ho, E. A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.041 · Cited by 67
Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Metadata
- Authors
- Jin, J., Zhou, K. K., Park, K., Hu, Y., Xu, X., Zheng, Z., Tyagi, P., Kompella, U. B., & Ma, J.-X.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-08-05
- Volume
- 52
- Issue
- 9
- Pages
- 6230
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W1967882436
- Cited by
- 48
- References
- 4
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.